Quintessence Publishing United Kingdom | Quintessence
Quintessence Publishing United Kingdom | Quintessence,Smith+Nephew's VISIONAIRE™ Patient-Specific Instrumentation,The Evolving Clinical and Pharmacoeconomic Impact of,Up to 8-year follow-up from RESONATE-2: first-line ibrutinib,P76.60 FLAIR: Phase II Study of Osimertinib plus Bevacizumab